Huilai Zhang

13PUBLICATIONS
26CO-AUTHORS
Haematological tumoursPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsLiquid biopsies
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Sep 30, 2025
Glofitamab vs. real-world regimens in Chinese patients with third- or later-line relapsed/refractory diffuse large B-cell lymphoma: an external control study.

Keshu Zhou, Huijing Wu, Xia Zhao

|Jul 08, 2025
Risk Stratification for Diffuse Large B-Cell Lymphoma by Integrating Interim 18F-FDG PET-CT Analysis and the NCCN-IPI: A Multicenter Retrospective Study.

Jiesong Wang, Yong Sun, Meifu Lin

|Mar 05, 2025
Comprehensive Analysis of Single-Cell and Bulk Transcriptomics Identified Regulatory T-Cell Features as Predictors of Prognosis in Diffuse Large B-Cell Lymphoma.

Yaoli Cui, Ge Hu, Xue Han

|Feb 06, 2025
Early Detection and Central Nervous System Prophylaxis in Patients With High-Risk Features of Primary Lymphoma of the Female Genital Tract: The Key to Improved Prognosis.

Bingyi Wang, Yaxiao Lu, Jing Zhao

|Dec 06, 2024
Efficacy and Safety of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone for Previously Untreated Diffuse Large B-Cell Lymphoma: A Real-World, Multi-Center, Retrospective Cohort Study.

Peiqi Zhao, Shu Zhao, Chen Huang

|May 31, 2024
Metabolic pathway-based subtyping reveals distinct microenvironmental states associated with diffuse large B-cell lymphoma outcomes.

Xiaohui Wang, Hengqi Liu, Yue Fei

Pageof 3

Frequent Collaborators

5 joint publications

Xianhuo Wang

3 joint publications

Xianhuo Wang

2 joint publications

Lanfang Li

1 joint publications

Zhengzi Qian